{"id":82,"date":"2023-07-10T11:30:59","date_gmt":"2023-07-10T10:30:59","guid":{"rendered":"https:\/\/tris.sambrownprojects.com\/?page_id=82"},"modified":"2024-06-05T17:14:58","modified_gmt":"2024-06-05T16:14:58","slug":"other-cns-disorders","status":"publish","type":"page","link":"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/","title":{"rendered":"Other CNS Disorders"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row el_class=&#8221;subnav-shortcode&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221;][vc_column][vc_column_text css=&#8221;.vc_custom_1692361070301{margin-bottom: 0px !important;}&#8221;]<div class=\"porto-block\" data-id=\"1137\">[vc_row full_width=\"stretch_row\" wrap_container=\"yes\" video_bg=\"yes\" video_bg_url=\"\/wp-content\/uploads\/2023\/07\/Interior_WhoWeAre-Optimized.mp4\" conditional_render=\"%5B%7B%22value_role%22%3A%22administrator%22%7D%5D\" el_class=\"subpage-banner subpage-who-we-are\"][vc_column width=\"1\/2\"][vc_custom_heading field_dynamic_source=\"post_info\" font_container=\"tag:h1|text_align:left\" use_theme_fonts=\"yes\" enable_field_dynamic=\"true\" field_dynamic_content=\"post_title\"][\/vc_column][vc_column width=\"1\/2\"][\/vc_column][\/vc_row][vc_row full_width=\"stretch_row\" wrap_container=\"yes\" conditional_render=\"%5B%7B%22value_role%22%3A%22administrator%22%7D%5D\" el_class=\"subpage-nav hide-mobile current-topnav\"][vc_column]<div class=\"widget_sidebar_menu main-sidebar-menu wpb_custom_fa56fd63c3b694fcdb3812eb30a338f1\"><div class=\"sidebar-menu-wrap\"><ul id=\"menu-subnav-pipeline\" class=\"sidebar-menu\"><li id=\"nav-menu-item-1030\" class=\"active-pipline menu-item menu-item-type-post_type menu-item-object-page  narrow \"><a href=\"https:\/\/www.trispharma.com\/pipeline\/\">Overview<\/a><\/li>\n<li id=\"nav-menu-item-2639\" class=\"menu-item menu-item-type-post_type menu-item-object-page  narrow \"><a href=\"https:\/\/www.trispharma.com\/pipeline\/adhd\/\">ADHD Pipeline<\/a><\/li>\n<li id=\"nav-menu-item-2641\" class=\"menu-item menu-item-type-post_type menu-item-object-page  narrow \"><a href=\"https:\/\/www.trispharma.com\/pipeline\/pain\/\">Pain Pipeline<\/a><\/li>\n<li id=\"nav-menu-item-2640\" class=\"menu-item menu-item-type-post_type menu-item-object-page  narrow \"><a href=\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/\">Other CNS Disorders<\/a><\/li>\n<li id=\"nav-menu-item-1031\" class=\"menu-item menu-item-type-post_type menu-item-object-page  narrow \"><a href=\"https:\/\/www.trispharma.com\/pipeline\/clinical-publications\/\">Clinical Publications<\/a><\/li>\n<\/ul><\/div><\/div>[\/vc_column][\/vc_row]<\/div>[\/vc_column_text][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1692004499906{margin-bottom: 0px !important;}&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221; el_class=&#8221;subpage-first-row .sp-first-row&#8221;][vc_column][vc_column_text css=&#8221;.vc_custom_1692004503345{margin-bottom: 0px !important;}&#8221;]<\/p>\n<h2>Our pipeline includes investigational therapies with demonstrated potential to address unmet needs in central nervous system (CNS) disorders including opioid use disorder (OUD), spasticity and narcolepsy.<\/h2>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;middle&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221; el_class=&#8221;rw-darkblue&#8221;][vc_column conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221;][vc_column_text el_class=&#8221;text-white phase-sp&#8221;]<\/p>\n<h6>PRECLINICAL<\/h6>\n<p>[\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1691894817615{margin-bottom: 30px !important;}&#8221; el_class=&#8221;text-white border-phase&#8221;][\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1711722160014{margin-bottom: 0px !important;}&#8221; el_class=&#8221;text-white&#8221;]<\/p>\n<h2>Cebranopadol<\/h2>\n<p><em>The first and only investigational dual nociceptin\/orphanin FQ peptide (NOP) receptor and \u00b5-opioid peptide (MOP) receptor agonist in clinical development for the treatment of OUD<\/em><\/p>\n<p>In addition to treating pain, cebranopadol has the potential to be a best-in-class treatment for OUD as demonstrated in validated preclinical models, in which the drug blocked self-administration of morphine, heroin and cocaine. Investigation of cebranopadol in OUD is supported by a grant received by the National Institute on Drug Abuse (NIDA).[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;middle&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221; el_class=&#8221;rw-lightblue&#8221;][vc_column conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221;][vc_column_text el_class=&#8221;text-white phase-sp&#8221;]<\/p>\n<h6>PHASE 1<\/h6>\n<p>[\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1691894817615{margin-bottom: 30px !important;}&#8221; el_class=&#8221;text-white border-phase&#8221;][\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1717603892137{margin-bottom: 0px !important;}&#8221; el_class=&#8221;text-white typo-notation&#8221;]<\/p>\n<h2>TRN-213<\/h2>\n<p><em>An optimized formulation designed to improve the delivery of the current standard of care for patients with spasticity associated with multiple sclerosis and other diseases such as cerebral palsy<\/em><\/p>\n<p>TRN-213 is designed to offer an extended-release treatment option, helping patients to achieve more consistent daily efficacy, higher adherence and a reduction in side effects.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;middle&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221; el_class=&#8221;rw-etxrablue rw-lightblue&#8221;][vc_column conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221;][vc_column_text el_class=&#8221;text-white phase-sp&#8221;]<\/p>\n<h6>PHASE 2<\/h6>\n<p>[\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1691894817615{margin-bottom: 30px !important;}&#8221; el_class=&#8221;text-white border-phase&#8221;][\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1692006749706{margin-bottom: 0px !important;}&#8221; el_class=&#8221;text-white&#8221;]<\/p>\n<h2>TRN-257<\/h2>\n<p><em>An investigational therapy for the treatment of narcolepsy, uniquely designed to provide clinically superior treatment as compared to existing options<\/em><\/p>\n<p>Currently available treatments, which contain high levels of sodium oxybate, are suboptimal due to dosing (requiring patients to take a second dose in the middle of the night), safety issues and significant side effects that impact an individual\u2019s quality of life. TRN-257 is designed to significantly improve the patient experience, containing very low sodium content and once-nightly dosing.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; wrap_container=&#8221;yes&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221; el_class=&#8221;gradient-global bottom-collout-cns mob-footercallout&#8221; css=&#8221;.vc_custom_1711722719792{margin-bottom: 50px !important;}&#8221;][vc_column width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221; el_class=&#8221;text-white quote-width&#8221;]<\/p>\n<h2>Investigational therapies with demonstrated potential to address unmet needs in CNS disorders including OUD, spasticity and narcolepsy.<\/h2>\n<p>[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row el_class=&#8221;subnav-shortcode&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221;][vc_column][vc_column_text css=&#8221;.vc_custom_1692361070301{margin-bottom: 0px !important;}&#8221;][\/vc_column_text][\/vc_column][\/vc_row][vc_row css=&#8221;.vc_custom_1692004499906{margin-bottom: 0px !important;}&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221; el_class=&#8221;subpage-first-row .sp-first-row&#8221;][vc_column][vc_column_text css=&#8221;.vc_custom_1692004503345{margin-bottom: 0px !important;}&#8221;] Our pipeline includes investigational therapies with demonstrated potential to address unmet needs in central nervous system (CNS) disorders including opioid use disorder (OUD), spasticity and narcolepsy. [\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row&#8221; equal_height=&#8221;yes&#8221; content_placement=&#8221;middle&#8221; conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221; el_class=&#8221;rw-darkblue&#8221;][vc_column conditional_render=&#8221;%5B%7B%22value_role%22%3A%22administrator%22%7D%5D&#8221;][vc_column_text el_class=&#8221;text-white phase-sp&#8221;] PRECLINICAL [\/vc_column_text][vc_column_text css=&#8221;.vc_custom_1691894817615{margin-bottom: 30px !important;}&#8221; [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":32,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-82","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n<title>CNS Disorders Pipeline | Tris Pharma<\/title>\n<meta name=\"description\" content=\"Learn about Tris Pharma&#039;s pipeline of investigational therapies targeting CNS disorders including opioid use disorder (OUD), spasticity, and narcolepsy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CNS Disorders Pipeline | Tris Pharma\" \/>\n<meta property=\"og:description\" content=\"Learn about Tris Pharma&#039;s pipeline of investigational therapies targeting CNS disorders including opioid use disorder (OUD), spasticity, and narcolepsy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/\" \/>\n<meta property=\"og:site_name\" content=\"Tris Pharma\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-05T16:14:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.trispharma.com\/wp-content\/uploads\/2024\/05\/Tris_OGImage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/\",\"url\":\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/\",\"name\":\"CNS Disorders Pipeline | Tris Pharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.trispharma.com\/#website\"},\"datePublished\":\"2023-07-10T10:30:59+00:00\",\"dateModified\":\"2024-06-05T16:14:58+00:00\",\"description\":\"Learn about Tris Pharma's pipeline of investigational therapies targeting CNS disorders including opioid use disorder (OUD), spasticity, and narcolepsy.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.trispharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\/\/www.trispharma.com\/pipeline\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Other CNS Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.trispharma.com\/#website\",\"url\":\"https:\/\/www.trispharma.com\/\",\"name\":\"Tris Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.trispharma.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n","yoast_head_json":{"title":"CNS Disorders Pipeline | Tris Pharma","description":"Learn about Tris Pharma's pipeline of investigational therapies targeting CNS disorders including opioid use disorder (OUD), spasticity, and narcolepsy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/","og_locale":"en_GB","og_type":"article","og_title":"CNS Disorders Pipeline | Tris Pharma","og_description":"Learn about Tris Pharma's pipeline of investigational therapies targeting CNS disorders including opioid use disorder (OUD), spasticity, and narcolepsy.","og_url":"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/","og_site_name":"Tris Pharma","article_modified_time":"2024-06-05T16:14:58+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.trispharma.com\/wp-content\/uploads\/2024\/05\/Tris_OGImage.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/","url":"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/","name":"CNS Disorders Pipeline | Tris Pharma","isPartOf":{"@id":"https:\/\/www.trispharma.com\/#website"},"datePublished":"2023-07-10T10:30:59+00:00","dateModified":"2024-06-05T16:14:58+00:00","description":"Learn about Tris Pharma's pipeline of investigational therapies targeting CNS disorders including opioid use disorder (OUD), spasticity, and narcolepsy.","breadcrumb":{"@id":"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.trispharma.com\/pipeline\/other-cns-disorders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.trispharma.com\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/www.trispharma.com\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Other CNS Disorders"}]},{"@type":"WebSite","@id":"https:\/\/www.trispharma.com\/#website","url":"https:\/\/www.trispharma.com\/","name":"Tris Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.trispharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/pages\/82"}],"collection":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/comments?post=82"}],"version-history":[{"count":24,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/pages\/82\/revisions"}],"predecessor-version":[{"id":2968,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/pages\/82\/revisions\/2968"}],"up":[{"embeddable":true,"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/pages\/32"}],"wp:attachment":[{"href":"https:\/\/www.trispharma.com\/wp-json\/wp\/v2\/media?parent=82"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}